Omeros’ (OMER) Hold Rating Reiterated at Needham & Company LLC

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reissued by research analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports.

Several other analysts have also issued reports on the company. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Price Performance

Shares of OMER opened at $8.01 on Tuesday. The company has a market cap of $464.18 million, a PE ratio of -3.47 and a beta of 2.03. The firm has a 50-day moving average of $8.61 and a 200-day moving average of $7.61. Omeros has a one year low of $2.97 and a one year high of $13.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Truvestments Capital LLC boosted its holdings in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares during the period. Quantbot Technologies LP acquired a new position in shares of Omeros in the 4th quarter valued at approximately $46,000. BNP Paribas Financial Markets lifted its holdings in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares during the period. Finally, Picton Mahoney Asset Management boosted its position in shares of Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.